Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029202 | 0.84 | GPR119 (0.53) | GPR119CHRM2CHRM1CHRM3SUV39H2 | |
| SCHEMBL5044687 | 0.83 | KCNH2 (0.44) | GPR119KCNH2 | |
| SCHEMBL720548 | 0.83 | CHRM2 (0.49) | GPR119CHRM2CHRM1CHRM3SUV39H2 | |
| SCHEMBL720547 | 0.83 | CHRM2 (0.49) | GPR119CHRM2CHRM1CHRM3SUV39H2 | |
| SCHEMBL10052777 | 0.83 | CHRM2 (0.49) | GPR119CHRM2CHRM1CHRM3SUV39H2 | |
| SCHEMBL20989499 | 0.81 | GPR119 (0.48) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL12093210 | 0.81 | GPR119 (0.52) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL12076859 | 0.81 | GPR119 (0.52) | GPR119CHRM2CHRM1CHRM3SUV39H2 | |
| SCHEMBL12094616 | 0.81 | GPR119 (0.52) | GPR119CHRM2CHRM1CHRM3SUV39H2 | |
| SCHEMBL1029892 | 0.80 | CHRM2 (0.48) | GPR119CHRM2CHRM1CHRM3SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957493-B1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | ORGANON NV (NL) | 2011-01-19 | — | — | EP | disclosed |
| US-7605170-B2 | 8-azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2009-10-20 | — | — | US | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | SLC22A8, SLCO1B3, SLCO1B1 | GPR119 2412/4885CHRM2 1718/4885CHRM1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.